|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
|
US4741900A
(en)
|
1982-11-16 |
1988-05-03 |
Cytogen Corporation |
Antibody-metal ion complexes
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
GB8430252D0
(en)
|
1984-11-30 |
1985-01-09 |
Beecham Group Plc |
Compounds
|
|
US5206344A
(en)
|
1985-06-26 |
1993-04-27 |
Cetus Oncology Corporation |
Interleukin-2 muteins and polymer conjugation thereof
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
JP2703764B2
(ja)
|
1986-04-28 |
1998-01-26 |
シータス オンコロジー コーポレイション |
補体成分Ｃ５ａに対するモノクローナル抗体
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US5256642A
(en)
|
1988-04-01 |
1993-10-26 |
The Johns Hopkins University |
Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
|
|
NZ230747A
(en)
|
1988-09-30 |
1992-05-26 |
Bror Morein |
Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5166322A
(en)
|
1989-04-21 |
1992-11-24 |
Genetics Institute |
Cysteine added variants of interleukin-3 and chemical modifications thereof
|
|
US5244800A
(en)
|
1990-04-27 |
1993-09-14 |
The Uab Research Foundation |
Crystals of human complement factor d that are triclinic
|
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
|
ATE255131T1
(de)
|
1991-06-14 |
2003-12-15 |
Genentech Inc |
Humanisierter heregulin antikörper
|
|
WO1993000109A1
(en)
|
1991-06-28 |
1993-01-07 |
Genentech, Inc. |
Method of stimulating immune response using growth hormone
|
|
FI941572L
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
|
|
WO1993016185A2
(en)
|
1992-02-06 |
1993-08-19 |
Creative Biomolecules, Inc. |
Biosynthetic binding protein for cancer marker
|
|
US5456909A
(en)
|
1992-08-07 |
1995-10-10 |
T Cell Sciences, Inc. |
Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
|
|
AU687755B2
(en)
|
1992-08-21 |
1998-03-05 |
Genentech Inc. |
Method for treating an LFA-1-mediated disorder
|
|
EP0679095A1
(en)
|
1992-11-25 |
1995-11-02 |
Amgen Boulder Inc. |
Modified insulin-like growth factors
|
|
US5861156A
(en)
|
1993-01-08 |
1999-01-19 |
Creative Biomolecules |
Methods of delivering agents to target cells
|
|
CN1134111A
(zh)
|
1993-04-07 |
1996-10-23 |
赛纳根公司 |
使用胰岛素样生长因子结合蛋白质的方法
|
|
US5856300A
(en)
|
1994-05-12 |
1999-01-05 |
T Cell Sciences, Inc. |
Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
|
|
US5679546A
(en)
|
1993-09-24 |
1997-10-21 |
Cytomed, Inc. |
Chimeric proteins which block complement activation
|
|
US5627264A
(en)
|
1994-03-03 |
1997-05-06 |
Alexion Pharmaceuticals, Inc. |
Chimeric complement inhibitor proteins
|
|
EP0751787B1
(en)
|
1994-03-23 |
2005-01-12 |
Alexion Pharmaceuticals, Inc. |
Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation
|
|
US5534615A
(en)
|
1994-04-25 |
1996-07-09 |
Genentech, Inc. |
Cardiac hypertrophy factor and uses therefor
|
|
US5919623A
(en)
|
1994-04-27 |
1999-07-06 |
St. James's And Seacroft University Hospitals Nhs Trust |
Nucleic acid mutation assays
|
|
US6074642A
(en)
|
1994-05-02 |
2000-06-13 |
Alexion Pharmaceuticals, Inc. |
Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
|
|
US5679345A
(en)
|
1994-06-02 |
1997-10-21 |
The Johns Hopkins University |
Method for preventing complement-dependent rejection of organ or tissue transplants
|
|
US5897475A
(en)
|
1994-10-05 |
1999-04-27 |
Antex Biologics, Inc. |
Vaccines comprising enhanced antigenic helicobacter spp.
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
|
AU718439B2
(en)
|
1995-09-21 |
2000-04-13 |
Genentech Inc. |
Human growth hormone variants
|
|
WO1999046281A2
(en)
|
1998-03-10 |
1999-09-16 |
Genentech, Inc. |
Novel polypeptides and nucleic acids encoding the same
|
|
WO2000036102A2
(en)
|
1998-12-16 |
2000-06-22 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
|
US7122636B1
(en)
|
1997-02-21 |
2006-10-17 |
Genentech, Inc. |
Antibody fragment-polymer conjugates and uses of same
|
|
WO1999040100A1
(en)
|
1998-02-09 |
1999-08-12 |
Human Genome Sciences, Inc. |
45 human secreted proteins
|
|
US20050197285A1
(en)
|
1997-03-07 |
2005-09-08 |
Rosen Craig A. |
Human secreted proteins
|
|
US6472520B2
(en)
|
1997-03-21 |
2002-10-29 |
The Trustees Of Columbia University In The City Of New York |
Rat PEG-3 promoter
|
|
WO1999027098A2
(en)
|
1997-11-21 |
1999-06-03 |
Genentech, Inc. |
A-33 related antigens and their pharmacological uses
|
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
|
IL132240A0
(en)
|
1997-04-07 |
2001-03-19 |
Genentech Inc |
Anti-vegf antibodies
|
|
US5994511A
(en)
|
1997-07-02 |
1999-11-30 |
Genentech, Inc. |
Anti-IgE antibodies and methods of improving polypeptides
|
|
CN1269805A
(zh)
|
1997-07-14 |
2000-10-11 |
博尔德生物技术公司 |
生长激素和相关蛋白的衍生物
|
|
EP1007092B1
(en)
|
1997-08-26 |
2006-08-09 |
Amgen Fremont Inc. |
A process for inhibiting complement activation via the alternative pathway
|
|
US6410708B1
(en)
|
1997-11-21 |
2002-06-25 |
Genentech, Inc. |
Nucleic acids encoding A-33 related antigen polypeptides
|
|
US7419663B2
(en)
|
1998-03-20 |
2008-09-02 |
Genentech, Inc. |
Treatment of complement-associated disorders
|
|
US8007798B2
(en)
|
1997-11-21 |
2011-08-30 |
Genentech, Inc. |
Treatment of complement-associated disorders
|
|
US8088386B2
(en)
|
1998-03-20 |
2012-01-03 |
Genentech, Inc. |
Treatment of complement-associated disorders
|
|
US7282565B2
(en)
|
1998-03-20 |
2007-10-16 |
Genentech, Inc. |
PRO362 polypeptides
|
|
US7192589B2
(en)
|
1998-09-16 |
2007-03-20 |
Genentech, Inc. |
Treatment of inflammatory disorders with STIgMA immunoadhesins
|
|
US7005504B2
(en)
|
1998-01-22 |
2006-02-28 |
Genentech, Inc. |
Antibody fragment-peg conjugates
|
|
JP4437192B2
(ja)
|
1998-02-20 |
2010-03-24 |
タノックス インコーポレイテッド |
補体活性化阻害剤
|
|
US7112327B2
(en)
|
1998-02-20 |
2006-09-26 |
Tanox, Inc. |
Inhibition of complement activation
|
|
US6956107B2
(en)
|
1998-02-20 |
2005-10-18 |
Tanox, Inc. |
Inhibitors of complement activation
|
|
AU5587799A
(en)
|
1998-08-27 |
2000-03-21 |
Incyte Pharmaceuticals, Inc. |
Protein transport-associated molecules
|
|
US6376653B1
(en)
|
1998-09-28 |
2002-04-23 |
Smithkline Beecham Plc |
Tie2 antagonist antibodies
|
|
IL143031A0
(en)
|
1998-12-22 |
2002-04-21 |
Genentech Inc |
Methods and compositions for inhibiting neoplastic cell growth
|
|
KR100940380B1
(ko)
|
1999-01-15 |
2010-02-02 |
제넨테크, 인크. |
효과기 기능이 변화된 폴리펩티드 변이체
|
|
CA2362427A1
(en)
|
1999-03-08 |
2000-09-14 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
|
ATE500328T1
(de)
|
1999-03-11 |
2011-03-15 |
Merck Serono Sa |
Vaskuläre adhesionsmoleküle und modulierung ihrer funktion
|
|
US6642353B1
(en)
|
1999-03-17 |
2003-11-04 |
Chugai Seiyaku Kabushiki Kaisha |
Peptide ligands for the erythropoietin receptor
|
|
AU2883900A
(en)
|
1999-07-07 |
2001-01-30 |
Genentech Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
|
EP1234030A4
(en)
|
1999-11-19 |
2003-05-07 |
Human Genome Sciences Inc |
18 HUMANE SECRETIED PROTEINS
|
|
EP1666494A1
(en)
|
1999-12-01 |
2006-06-07 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
|
EP1253946A2
(en)
|
2000-02-10 |
2002-11-06 |
Alexion Pharmaceuticals, Inc. |
Mixtures of caspase inhibitors and complement inhibitors and methods of use thereof
|
|
US6821775B1
(en)
|
2000-02-11 |
2004-11-23 |
Genvec, Inc. |
Viral vector encoding pigment epithelium-derived factor
|
|
PT1265929E
(pt)
|
2000-03-23 |
2009-10-15 |
Genentech Inc |
Inibidores anti-c2/c2a de activação complementar
|
|
DK2026073T3
(en)
|
2000-04-29 |
2016-07-25 |
Univ Iowa Res Found |
Diagnosis and treatment of macular degeneration-related disorders
|
|
CA2412211A1
(en)
|
2000-06-23 |
2002-01-03 |
Genetech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
|
JP2004516013A
(ja)
|
2000-07-20 |
2004-06-03 |
ジェネンテック・インコーポレーテッド |
血管形成に関連する障害を診断及び治療するための組成物と方法
|
|
EP2113516B1
(en)
|
2000-10-10 |
2014-05-21 |
Genentech, Inc. |
Antibodies against C5 inhibiting type II endothelial cell activation
|
|
JP4340062B2
(ja)
|
2000-10-12 |
2009-10-07 |
ジェネンテック・インコーポレーテッド |
粘度の減少した濃縮タンパク質製剤
|
|
TR200300478T2
(tr)
|
2000-10-13 |
2004-10-21 |
Biogen Inc. |
Hümanize antiLT-ß-R antikorları
|
|
KR20100031769A
(ko)
|
2000-12-28 |
2010-03-24 |
알투스 파마슈티컬스 인코포레이티드 |
전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
|
|
US20040077575A1
(en)
|
2002-01-11 |
2004-04-22 |
Giordano Giovan Giacomo |
Inhibition of pathological angiogenesis in vivo
|
|
US6867189B2
(en)
|
2001-07-26 |
2005-03-15 |
Genset S.A. |
Use of adipsin/complement factor D in the treatment of metabolic related disorders
|
|
CA2457461C
(en)
|
2001-08-17 |
2013-12-24 |
Tanox, Inc. |
Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b
|
|
WO2003029420A2
(en)
|
2001-10-02 |
2003-04-10 |
Genentech, Inc. |
Apo-2 ligand variants and uses thereof
|
|
EP2500032A1
(en)
|
2002-06-24 |
2012-09-19 |
Genentech, Inc. |
APO-2 ligand/trail variants and uses thereof
|
|
EP1575514A2
(en)
|
2002-07-31 |
2005-09-21 |
Seattle Genetics, Inc. |
Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
|
|
TWI323265B
(en)
|
2002-08-06 |
2010-04-11 |
Glaxo Group Ltd |
Antibodies
|
|
WO2004022594A2
(en)
|
2002-09-06 |
2004-03-18 |
Cytos Biotechnology Ag |
Immune modulatory compounds and methods
|
|
WO2004041160A2
(en)
|
2002-10-30 |
2004-05-21 |
University Of Kentucky Research Foundation |
Methods and animal model for analyzing age-related macular degeneration
|
|
US7816497B2
(en)
|
2002-10-30 |
2010-10-19 |
University Of Kentucky |
Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration
|
|
EP1601377A4
(en)
|
2003-02-21 |
2009-07-15 |
Genentech Inc |
METHOD FOR THE PREVENTION AND TREATMENT OF TISSUE DAMAGE IN CONNECTION WITH ISCHEMIC REPERFUSION DAMAGE
|
|
RU2232991C1
(ru)
|
2003-04-09 |
2004-07-20 |
Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" |
Способ определения функциональной активности фактора d комплемента человека
|
|
KR100512483B1
(ko)
|
2003-05-07 |
2005-09-05 |
선바이오(주) |
신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법
|
|
US7709610B2
(en)
|
2003-05-08 |
2010-05-04 |
Facet Biotech Corporation |
Therapeutic use of anti-CS1 antibodies
|
|
SI1639011T1
(sl)
*
|
2003-06-30 |
2009-04-30 |
Domantis Ltd |
Pegilirana protitelesa z enojno domeno (dAb)
|
|
WO2005014849A2
(en)
|
2003-07-03 |
2005-02-17 |
Euro-Celtique, S.A. |
Genes associated with responses to neuropathic pain
|
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
|
WO2005044853A2
(en)
|
2003-11-01 |
2005-05-19 |
Genentech, Inc. |
Anti-vegf antibodies
|
|
US7923010B2
(en)
|
2003-09-11 |
2011-04-12 |
The Board Of Regents Of The University Of Texas System |
Methods and materials for treating autoimmune diseases and conditions
|
|
US20050169921A1
(en)
|
2004-02-03 |
2005-08-04 |
Leonard Bell |
Method of treating hemolytic disease
|
|
US7127355B2
(en)
|
2004-03-05 |
2006-10-24 |
Perlegen Sciences, Inc. |
Methods for genetic analysis
|
|
US20090087854A1
(en)
|
2007-09-27 |
2009-04-02 |
Perlegen Sciences, Inc. |
Methods for genetic analysis
|
|
US7794713B2
(en)
|
2004-04-07 |
2010-09-14 |
Lpath, Inc. |
Compositions and methods for the treatment and prevention of hyperproliferative diseases
|
|
ES2579805T3
(es)
|
2004-09-23 |
2016-08-16 |
Genentech, Inc. |
Anticuerpos y conjugados modificados por ingeniería genética con cisteína
|
|
AU2005314461B2
(en)
|
2004-11-18 |
2012-02-02 |
The Rockefeller University |
Methods and compositions for treating ocular disorders
|
|
WO2006071856A2
(en)
|
2004-12-23 |
2006-07-06 |
Glycofi, Inc. |
Immunoglobulins comprising predominantly a man5glcnac2 glycoform
|
|
JP5068175B2
(ja)
|
2005-01-04 |
2012-11-07 |
日立化成工業株式会社 |
プライマー生成ローリングサークル型増幅
|
|
US8088579B2
(en)
|
2005-02-14 |
2012-01-03 |
University Of Iowa Research Foundation |
Complement factor H for diagnosis of age-related macular degeneration
|
|
CA2725709A1
(en)
|
2005-06-08 |
2006-12-14 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Educatio N |
Susceptibility genes for age-related maculopathy (arm) on chromosome 10q26
|
|
CA2625206C
(en)
|
2005-10-08 |
2021-12-07 |
Potentia Pharmaceuticals, Inc. |
Compstatin and analogs thereof for eye disorders
|
|
PT2500030E
(pt)
|
2005-11-04 |
2015-09-24 |
Genentech Inc |
Uso de inibidores da via do complemento para tratar doenças oculares
|
|
US20070190057A1
(en)
|
2006-01-23 |
2007-08-16 |
Jian Wu |
Methods for modulating mannose content of recombinant proteins
|
|
AR059066A1
(es)
|
2006-01-27 |
2008-03-12 |
Amgen Inc |
Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
|
|
US20080146501A1
(en)
|
2006-02-13 |
2008-06-19 |
University Of Iowa Research Foundation |
Protective complement proteins and age-related macular degeneration
|
|
MX2008012617A
(es)
|
2006-03-31 |
2008-10-10 |
Novartis Ag |
Compuestos organicos.
|
|
SI2944306T1
(sl)
|
2006-06-16 |
2021-04-30 |
Regeneron Pharmaceuticals, Inc. |
Formulacije antagonista VEGF, primerne za intravitrealno dajanje
|
|
AU2007300221A1
(en)
*
|
2006-09-25 |
2008-04-03 |
Medimmune, Llc. |
Stabilized antibody formulations and uses thereof
|
|
PL2907827T3
(pl)
|
2006-11-02 |
2019-03-29 |
Genentech, Inc. |
Humanizowane przeciwciała przeciw czynnikowi D i ich zastosowanie
|
|
WO2008140793A2
(en)
|
2007-05-11 |
2008-11-20 |
Tufts Medical Center |
Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk
|
|
AR066660A1
(es)
*
|
2007-05-23 |
2009-09-02 |
Genentech Inc |
Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
|
|
KR101264473B1
(ko)
*
|
2007-05-24 |
2013-05-29 |
아블린쓰 엔.브이. |
Ｒａｎｋ-ｌ에 대한 아미노산 서열, 및 이를 포함하는 골 질환 및 장애 치료용 폴리펩티드
|
|
US20090203001A1
(en)
|
2007-08-24 |
2009-08-13 |
The Regents Of The University Of Michigan |
Compositions and methods for diagnosing and treating macular degeneration
|
|
WO2009146204A1
(en)
|
2008-04-18 |
2009-12-03 |
Tufts Medical Center |
Polymorphisms associated with age-related macular degeneration and methods for evaluating patient risk
|
|
CR20170001A
(es)
|
2008-04-28 |
2017-08-10 |
Genentech Inc |
Anticuerpos anti factor d humanizados
|
|
US20110294682A1
(en)
|
2008-04-28 |
2011-12-01 |
The General Hospital Corporation |
Polynucleotides Associated With Age-Related Macular Degeneration and Methods for Evaluating Patient Risks
|
|
CN101724144A
(zh)
|
2008-11-03 |
2010-06-09 |
北京键凯科技有限公司 |
新型的多臂聚乙二醇及其制备方法和应用
|
|
CA2740242A1
(en)
|
2008-11-05 |
2010-05-14 |
Genentech, Inc. |
Genetic polymorphisms in age-related macular degeneration
|
|
US20120115925A1
(en)
|
2008-12-23 |
2012-05-10 |
Massachusetts Eye And Ear Infirmary |
Allelic Variants Associated with Advanced Age-Related Macular Degeneration
|
|
MX2011006726A
(es)
|
2009-01-02 |
2011-07-20 |
Alcon Res Ltd |
Implante oftalmico recargable in situ.
|
|
WO2010085542A2
(en)
|
2009-01-23 |
2010-07-29 |
Novartis Ag |
Biomarkers related to age-related macular degeneration (amd)
|
|
CA3045436C
(en)
|
2009-01-29 |
2025-10-07 |
Forsight Vision4, Inc. |
ADMINISTRATION OF A MEDICATION IN THE POSTERIOR SEGMENT
|
|
WO2010132459A2
(en)
|
2009-05-11 |
2010-11-18 |
Cleveland Clinic Foundation |
Biomarkers for assessment of age-related macular degeneration
|
|
EP3739056A1
(en)
|
2009-07-02 |
2020-11-18 |
LanzaTech New Zealand Limited |
Alcohol production process
|
|
CA2781595C
(en)
|
2009-07-10 |
2016-07-05 |
The Regents Of The University Of Michigan |
Compositions and methods for diagnosing and treating macular degeneration
|
|
WO2011017229A2
(en)
|
2009-08-06 |
2011-02-10 |
Tufts - New England Medical Center |
Plasma complement components as expression markers for age-related macular degeneration and related phenotypes
|
|
CN102638986A
(zh)
|
2009-08-12 |
2012-08-15 |
纯生物科学 |
采用无水消毒剂的制剂和方法
|
|
US20110165648A1
(en)
|
2009-11-04 |
2011-07-07 |
Menno Van Lookeren Campagne |
Co-crystal structure of factor D and anti-factor D antibody
|
|
NZ599438A
(en)
*
|
2009-11-19 |
2013-12-20 |
Merck Serono Sa |
Humanized antibodies against human il-22ra
|
|
RU2016105962A
(ru)
|
2009-12-04 |
2018-11-23 |
Дженентек, Инк. |
Мультиспецифические антитела, аналоги антител, композиции и способы
|
|
CN102108119A
(zh)
|
2009-12-25 |
2011-06-29 |
天津键凯科技有限公司 |
多臂聚乙二醇衍生物及其与药物的结合物和凝胶
|
|
WO2012031273A2
(en)
*
|
2010-09-03 |
2012-03-08 |
Stem Centrx, Inc. |
Novel modulators and methods of use
|
|
MX348025B
(es)
|
2010-11-01 |
2017-05-24 |
Genentech Inc * |
Prediccion del paso a degeneracion macular avanzada relacionada con la edad utilizando una puntuacion poligenica.
|
|
US8628773B2
(en)
*
|
2011-04-07 |
2014-01-14 |
Amgen Inc. |
Antigen binding proteins
|
|
MX390891B
(es)
|
2011-10-14 |
2025-03-19 |
Genentech Inc |
ANTICUERPOS ANTI-HtrA1 Y MÉTODOS DE USO.
|
|
JP6051998B2
(ja)
|
2012-03-30 |
2016-12-27 |
日油株式会社 |
マルチアーム型ポリエチレングリコール誘導体、その中間体及び製造方法
|
|
MD20180107A2
(ro)
*
|
2013-03-18 |
2019-06-30 |
Biocerox Products B.V. |
Anticorpi anti-CD134 (OX40) umanizaţi şi utilizarea acestora
|
|
CR20160132A
(es)
|
2013-08-12 |
2016-08-25 |
Genentech Inc |
Composiciones y método para tratar condiciones asociadas con el complemento
|
|
EP3761033A3
(en)
*
|
2013-09-06 |
2021-01-20 |
F. Hoffmann-La Roche AG |
Method for improving antibody stability
|
|
AR099625A1
(es)
*
|
2014-03-21 |
2016-08-03 |
Lilly Co Eli |
Anticuerpos de il-21
|
|
KR20160147855A
(ko)
*
|
2014-05-01 |
2016-12-23 |
제넨테크, 인크. |
항-인자 d 항체 변이체 및 이의 용도
|
|
AU2016344146A1
(en)
|
2015-10-30 |
2018-05-10 |
Genentech, Inc. |
Methods of measuring Factor D activity and potency of Factor D inhibitors
|
|
HK1257422A1
(zh)
|
2015-10-30 |
2019-10-18 |
豪夫迈‧罗氏有限公司 |
抗-因子d抗体变体缀合物及其用途
|
|
EP3368074A2
(en)
|
2015-10-30 |
2018-09-05 |
Hoffmann-La Roche AG |
Anti-factor d antibodies and conjugates
|
|
MX2018005226A
(es)
|
2015-10-30 |
2019-04-29 |
Genentech Inc |
Formulaciones de anticuerpo anti-factor d.
|